EA200100539A1 - Новый способ лечения - Google Patents

Новый способ лечения

Info

Publication number
EA200100539A1
EA200100539A1 EA200100539A EA200100539A EA200100539A1 EA 200100539 A1 EA200100539 A1 EA 200100539A1 EA 200100539 A EA200100539 A EA 200100539A EA 200100539 A EA200100539 A EA 200100539A EA 200100539 A1 EA200100539 A1 EA 200100539A1
Authority
EA
Eurasian Patent Office
Prior art keywords
blood plasma
concentration
insulin sensitizer
diabetes mellitus
treatment
Prior art date
Application number
EA200100539A
Other languages
English (en)
Other versions
EA009192B1 (ru
Inventor
Лиза Бенинкоса
Уилльям Джаско
Original Assignee
Смитклайн Бичам Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10842389&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA200100539(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Смитклайн Бичам Корпорейшн filed Critical Смитклайн Бичам Корпорейшн
Publication of EA200100539A1 publication Critical patent/EA200100539A1/ru
Publication of EA009192B1 publication Critical patent/EA009192B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Abstract

Способ лечения сахарного диабета 2 типа и состояний, связанных с сахарным диабетом, при этом способ включает в себя введение нуждающемуся в этом человеку или млекопитающему эффективного нетоксичного количества инсулинового сенсибилизатора таким образом, чтобы обеспечить концентрацию инсулинового сенсибилизатора в плазме крови, по меньшей мере, на пороговом уровне ("пороговая концентрация в плазме крови") в пределах интервала эффективных уровней инсулинового сенсибилизатора в плазме крови, композиции для использования в таком способе и методология определения концентраций активного агента в плазме крови, использованная в таких способах.Отчет о международном поиске был опубликован 2000.09.08.
EA200100539A 1998-11-12 1999-11-12 Способ лечения сахарного диабета типа 2 EA009192B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9824893.3A GB9824893D0 (en) 1998-11-12 1998-11-12 Novel method of treatment
PCT/US1999/026746 WO2000027341A2 (en) 1998-11-12 1999-11-12 Novel method of treatment

Publications (2)

Publication Number Publication Date
EA200100539A1 true EA200100539A1 (ru) 2001-12-24
EA009192B1 EA009192B1 (ru) 2007-12-28

Family

ID=10842389

Family Applications (2)

Application Number Title Priority Date Filing Date
EA200700968A EA200700968A1 (ru) 1998-11-12 1999-11-12 Фармацевтическая композиция для лечения сахарного диабета 2 типа
EA200100539A EA009192B1 (ru) 1998-11-12 1999-11-12 Способ лечения сахарного диабета типа 2

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA200700968A EA200700968A1 (ru) 1998-11-12 1999-11-12 Фармацевтическая композиция для лечения сахарного диабета 2 типа

Country Status (40)

Country Link
EP (2) EP1759698A1 (ru)
JP (1) JP2003521455A (ru)
KR (2) KR20010080440A (ru)
CN (3) CN101244062A (ru)
AP (2) AP2005003432A0 (ru)
AR (2) AR029149A1 (ru)
AT (1) ATE366573T1 (ru)
AU (1) AU768303B2 (ru)
BG (2) BG110061A (ru)
BR (1) BR9915284A (ru)
CA (1) CA2350425C (ru)
CO (1) CO5150158A1 (ru)
CY (1) CY1106892T1 (ru)
CZ (1) CZ299801B6 (ru)
DE (1) DE69936533T2 (ru)
DK (1) DK1135128T3 (ru)
DZ (1) DZ2938A1 (ru)
EA (2) EA200700968A1 (ru)
ES (1) ES2289833T3 (ru)
GB (1) GB9824893D0 (ru)
HK (1) HK1041202B (ru)
HR (1) HRP20010344B1 (ru)
HU (1) HUP0104262A3 (ru)
IL (1) IL143088A0 (ru)
MA (1) MA26759A1 (ru)
MY (1) MY128347A (ru)
NO (1) NO328391B1 (ru)
NZ (1) NZ527132A (ru)
OA (1) OA12193A (ru)
PE (1) PE20001239A1 (ru)
PL (1) PL349421A1 (ru)
PT (1) PT1135128E (ru)
RS (1) RS50130B (ru)
SK (1) SK286357B6 (ru)
TR (1) TR200101348T2 (ru)
TW (1) TWI234456B (ru)
UA (1) UA79730C2 (ru)
UY (2) UY25797A1 (ru)
WO (1) WO2000027341A2 (ru)
ZA (1) ZA200103793B (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY125516A (en) 1999-11-16 2006-08-30 Smithkline Beecham Plc Novel composition based on thiazolidinedione and metformin and use
US20050107450A1 (en) * 2001-12-21 2005-05-19 Brown Kathleen K. Dosing regimen for ppar-gamma activators
WO2012074375A1 (en) * 2010-12-01 2012-06-07 N.V. Nutricia Prevention or treatment of overweight and obesity in type 2 diabetic patients

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5522636A (en) * 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
JPS5697277A (en) * 1980-01-07 1981-08-05 Takeda Chem Ind Ltd Thiazolidine derivative
JPS6051189A (ja) * 1983-08-30 1985-03-22 Sankyo Co Ltd チアゾリジン誘導体およびその製造法
US4582839A (en) * 1984-03-21 1986-04-15 Takeda Chemical Industries, Ltd. 2,4-thiazolidinediones
CN1003445B (zh) * 1984-10-03 1989-03-01 武田药品工业株式会社 噻唑烷二酮衍生物，其制备方法和用途
JPH06779B2 (ja) * 1985-06-10 1994-01-05 武田薬品工業株式会社 チアゾリジオン誘導体およびそれを含んでなる医薬組成物
US4812570A (en) * 1986-07-24 1989-03-14 Takeda Chemical Industries, Ltd. Method for producing thiazolidinedione derivatives
DE3856378T2 (de) * 1987-09-04 2000-05-11 Beecham Group Plc Substituierte Thiazolidindionderivate
US4791125A (en) * 1987-12-02 1988-12-13 Pfizer Inc. Thiazolidinediones as hypoglycemic and anti-atherosclerosis agents
WO1989008650A1 (en) * 1988-03-08 1989-09-21 Pfizer Inc. Thiazolidinedione hypoglycemic agents
WO1989008651A1 (en) * 1988-03-08 1989-09-21 Pfizer Inc. Hypoglycemic thiazolidinedione derivatives
GB8919417D0 (en) * 1989-08-25 1989-10-11 Beecham Group Plc Novel compounds
WO1991007107A1 (en) * 1989-11-13 1991-05-30 Pfizer Inc. Oxazolidinedione hypoglycemic agents
JPH0469331A (ja) * 1990-07-10 1992-03-04 Asahi Chem Ind Co Ltd 徐放性エマルジョン製剤
JP2572673B2 (ja) * 1990-07-25 1997-01-16 エスエス製薬株式会社 徐放性錠剤
JPH04210683A (ja) * 1990-12-06 1992-07-31 Terumo Corp チアゾリジン−２，４−ジオン誘導体およびこれを含有する糖尿病合併症治療薬
US5183823A (en) * 1991-04-11 1993-02-02 Takeda Chemical Industries, Ltd. Pyridine n-oxide compounds which are useful as hypoglycemic and hypolipidemic agents
FR2680512B1 (fr) * 1991-08-20 1995-01-20 Adir Nouveaux derives de 2,4-thiazolidinedione, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
EP0601001B1 (en) * 1991-08-26 1997-04-16 PHARMACIA & UPJOHN COMPANY Liquid food product containing 3-guanidinopropionic acid
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
US5506245A (en) * 1992-10-12 1996-04-09 Adir Et Compagnie Thiazolidinedione compounds
US5478853A (en) * 1992-10-12 1995-12-26 Adir Et Compagnie Thazolidinedione compounds
CA2115587A1 (en) * 1993-02-18 1994-08-19 Hayato Kihara Styrene copolymers, polystyrene compositions, processes for producing styrene copolymers, and injection-molded articles
DE4317320A1 (de) * 1993-05-25 1994-12-01 Boehringer Mannheim Gmbh Neue Thiazolidindione und diese enthaltende Arzneimittel
AU679572B2 (en) * 1993-09-15 1997-07-03 Daiichi Sankyo Company, Limited Use of thiazolidinediones to prevent or delay onset of NIDDM
US5478852C1 (en) * 1993-09-15 2001-03-13 Sankyo Co Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of impaired glucose tolerance in order to prevent or delay the onset of noninsulin-dependent diabetes mellitus
US5902726A (en) * 1994-12-23 1999-05-11 Glaxo Wellcome Inc. Activators of the nuclear orphan receptor peroxisome proliferator-activated receptor gamma
US5708012A (en) * 1995-04-28 1998-01-13 Sankyo Company, Limited Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of insulin resistant subjects with normal glucose tolerance in order to prevent or delay the onset of noninsulin-dependent mellitus
US5859037A (en) * 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes
US6011049A (en) * 1997-02-19 2000-01-04 Warner-Lambert Company Combinations for diabetes

Also Published As

Publication number Publication date
NO20012301L (no) 2001-07-09
DK1135128T3 (da) 2007-11-05
CN101244062A (zh) 2008-08-20
CA2350425C (en) 2009-06-02
NZ527132A (en) 2005-01-28
EA200700968A1 (ru) 2008-06-30
IL143088A0 (en) 2002-11-10
HUP0104262A3 (en) 2003-06-30
KR20070048279A (ko) 2007-05-08
EP1135128A4 (en) 2003-07-16
HUP0104262A2 (en) 2002-08-28
BG110061A (bg) 2008-12-30
UY25797A1 (es) 2000-12-29
CZ299801B6 (cs) 2008-11-26
CA2350425A1 (en) 2000-05-18
NO328391B1 (no) 2010-02-08
YU37401A (sh) 2005-07-19
HRP20010344B1 (en) 2008-02-29
GB9824893D0 (en) 1999-01-06
AP2005003432A0 (en) 2005-12-31
AR029149A1 (es) 2003-06-18
ATE366573T1 (de) 2007-08-15
CN1354661A (zh) 2002-06-19
SK286357B6 (sk) 2008-08-05
EA009192B1 (ru) 2007-12-28
EP1759698A1 (en) 2007-03-07
HK1041202B (zh) 2007-10-05
CO5150158A1 (es) 2002-04-29
PL349421A1 (en) 2002-07-29
UA79730C2 (en) 2007-07-25
EP1135128B1 (en) 2007-07-11
PT1135128E (pt) 2007-10-12
ES2289833T3 (es) 2008-02-01
DE69936533T2 (de) 2008-03-13
TR200101348T2 (tr) 2002-02-21
DZ2938A1 (fr) 2004-03-15
AR029317A1 (es) 2003-06-25
HK1041202A1 (en) 2002-07-05
WO2000027341A2 (en) 2000-05-18
JP2003521455A (ja) 2003-07-15
PE20001239A1 (es) 2000-12-24
EP1135128A2 (en) 2001-09-26
MA26759A1 (fr) 2004-12-20
HRP20010344A2 (en) 2002-06-30
MY128347A (en) 2007-01-31
CZ20011656A3 (cs) 2002-06-12
TWI234456B (en) 2005-06-21
ZA200103793B (en) 2002-06-05
AU1719600A (en) 2000-05-29
BG65577B1 (bg) 2009-01-30
UY25801A1 (es) 2000-08-21
CY1106892T1 (el) 2012-01-25
KR20010080440A (ko) 2001-08-22
WO2000027341A3 (en) 2000-09-08
CN1235586C (zh) 2006-01-11
SK6422001A3 (en) 2001-12-03
BG105569A (en) 2002-01-31
AP1580A (en) 2006-02-24
CN1771943A (zh) 2006-05-17
NO20012301D0 (no) 2001-05-10
OA12193A (en) 2006-05-09
DE69936533D1 (de) 2007-08-23
RS50130B (sr) 2009-03-25
BR9915284A (pt) 2002-02-13
AU768303B2 (en) 2003-12-04

Similar Documents

Publication Publication Date Title
EA200101089A1 (ru) Новый способ лечения
NO976063L (no) Fremgangsmåte for behandling av diabetes
AR057631A1 (es) Composiciones y metodos para incrementar la sensibilidad a insulina
EA200000041A1 (ru) Способ лечения диабета тиазолидиндионом и метформином
BR0111800A (pt) Combinações de inibidores de depeptidil peptidase iv e outros agentes antidiabéticos para o tratamento de diabete mellitus
SE9404196D0 (sv) New antithrombotic formulation
ID30237A (id) KOMBINASI PENGHAMBAT-PENGHAMBAT FBPase DAN PEMEKA-PEMEKA INSULIN UNTUK PENGOBATAN DIABETES
KR890011606A (ko) 항응고제
Kompa et al. Effect of different irrigating solutions on aqueous humour pH changes, intraocular pressure and histological findings after induced alkali burns
DK261490D0 (da) New pharmaceutical compound
NO20020056D0 (no) Fremgangsmåte og system for anvendelse ved behandling av en pasient med et hvilket som helst medikament for å optimalisereterapien og forhindre en negativ medikamentrespons
BR9808221A (pt) Método de tratamento de tumor.
CY1107745T1 (el) Αγωγη του διαβητη με θειαζολιδινοδιονη και σουλφονυλουρια
EA200000042A1 (ru) Способ лечения диабета росиглитазоном и инсулином
KR950703353A (ko) 인슐린-의존적 진성 당뇨병을 예방 또는 치료하기 위한 인터루킨-10의 용도(Use of IL-10 to prevent or treat insulin-dependent diabetes mellitus)
EA200100539A1 (ru) Новый способ лечения
BR9810292A (pt) Tratamento de diabete com tiazolidinadiona, secretagogo de insulina e inibidor de alfa-glicosidase
EA199800821A1 (ru) Способ лечения аутизма
KR920003977A (ko) 신장질환치료제
EA200300222A1 (ru) Лечение гепатита c с помощью тимозина, интерферона и рибавирина
EA200000419A1 (ru) Применение тиазолидиндионов для лечения гипергликемии
TH59780B (th) วิธีบำบัดวิธีใหม่
TH59780A3 (th) วิธีบำบัดวิธีใหม่
ECSP993217A (es) Nuevo metodo tratamiento vii
EA200000418A1 (ru) Применение тиазолидиндионов для лечения гипергликемии

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU